Justin C Kao1, Adipong Brickshawana2, Teerin Liewluck3. 1. Department of Neurology, Auckland City Hospital, Auckland, New Zealand. 2. Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA. 3. Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN, USA. liewluck.teerin@mayo.edu.
Abstract
PURPOSE OF REVIEW: In recent years, immune checkpoint inhibitors have been increasingly used in patients with metastatic cancers with favorable oncological outcomes; however, there have also been increasing number of cancer survivors who have developed immune-related adverse events. Little is known about PD-1 inhibitor-associated neuromuscular complications. RECENT FINDINGS: Neuromuscular disorders are the most common neurological complication reported in PD-1 inhibitor-treated patients. Myasthenia gravis, immune-mediated myopathies, and Guillain-Barre syndrome are among commonly reported immune-related neuromuscular complications. HyperCKemia occurs frequently in patients with PD-1 inhibitor-associated myasthenia gravis, indicating coexisting myopathies or myocarditis. Oculobulbar weakness is a unique and common presentation of PD-1 inhibitor-associated immune-mediated myopathies with or without concomitant myasthenia gravis. High-dose steroid monotherapy may be associated with clinical deterioration in some patients with PD-1 inhibitor-associated myasthenia gravis, immune-mediated myopathies, or Guillain-Barre syndrome. PD-1 inhibitor-associated neuromuscular complications have some characteristic features compared to their idiopathic counterparts. Although steroid monotherapy is commonly used in non-neuromuscular autoimmune disorders triggered by anti-PD-1 therapy, this may lead to unfavorable outcomes in some patients with PD-1 inhibitor-associated neuromuscular complications.
PURPOSE OF REVIEW: In recent years, immune checkpoint inhibitors have been increasingly used in patients with metastatic cancers with favorable oncological outcomes; however, there have also been increasing number of cancer survivors who have developed immune-related adverse events. Little is known about PD-1 inhibitor-associated neuromuscular complications. RECENT FINDINGS:Neuromuscular disorders are the most common neurological complication reported in PD-1 inhibitor-treated patients. Myasthenia gravis, immune-mediated myopathies, and Guillain-Barre syndrome are among commonly reported immune-related neuromuscular complications. HyperCKemia occurs frequently in patients with PD-1 inhibitor-associated myasthenia gravis, indicating coexisting myopathies or myocarditis. Oculobulbar weakness is a unique and common presentation of PD-1 inhibitor-associated immune-mediated myopathies with or without concomitant myasthenia gravis. High-dose steroid monotherapy may be associated with clinical deterioration in some patients with PD-1 inhibitor-associated myasthenia gravis, immune-mediated myopathies, or Guillain-Barre syndrome. PD-1 inhibitor-associated neuromuscular complications have some characteristic features compared to their idiopathic counterparts. Although steroid monotherapy is commonly used in non-neuromuscular autoimmune disorders triggered by anti-PD-1 therapy, this may lead to unfavorable outcomes in some patients with PD-1 inhibitor-associated neuromuscular complications.
Authors: Nikeshan Jeyakumar; Mikel Etchegaray; Jason Henry; Laura Lelenwa; Bihong Zhao; Ana Segura; L Maximilian Buja Journal: Case Reports Immunol Date: 2020-07-04
Authors: William Damsky; Lucia Jilaveanu; Noel Turner; Curtis Perry; Christopher Zito; Mary Tomayko; Jonathan Leventhal; Kevan Herold; Eric Meffre; Marcus Bosenberg; Harriet M Kluger Journal: J Immunother Cancer Date: 2019-06-14 Impact factor: 13.751
Authors: Sonja E Leonhard; Melissa R Mandarakas; Francisco A A Gondim; Kathleen Bateman; Maria L B Ferreira; David R Cornblath; Pieter A van Doorn; Mario E Dourado; Richard A C Hughes; Badrul Islam; Susumu Kusunoki; Carlos A Pardo; Ricardo Reisin; James J Sejvar; Nortina Shahrizaila; Cristiane Soares; Thirugnanam Umapathi; Yuzhong Wang; Eppie M Yiu; Hugh J Willison; Bart C Jacobs Journal: Nat Rev Neurol Date: 2019-09-20 Impact factor: 42.937
Authors: Houssein Safa; Daniel H Johnson; Van Anh Trinh; Theresa E Rodgers; Heather Lin; Maria E Suarez-Almazor; Faisal Fa'ak; Chantal Saberian; Cassian Yee; Michael A Davies; Sudhakar Tummala; Karin Woodman; Noha Abdel-Wahab; Adi Diab Journal: J Immunother Cancer Date: 2019-11-21 Impact factor: 13.751